Compare Hut 8 Corp (HUT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Hut 8 Corp trades at $92.32 (market cap $10.56B), while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 12.6× Hut 8 Corp's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals.
| HUT | VRTX | |
|---|---|---|
Market Cap | $10.56B | $132.79B |
Sector | Technology | Health |
52-Week High | $133.02 | $529.65 |
52-Week Low | $21.37 | $376.62 |
Enterprise Value | $17.99B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $88.59, down 2.27% today amid bearish technical signals and mixed quarterly earnings. The stock faces headwinds from negative net income margins and cash burn, but maintains strong analyst support with a 93.75% buy rating and a $165.11 consensus price target. Recent news highlights institutional accumulation and a strategic pivot to AI data centers, backed by a $26.6 billion contracted backlog.
Outlook hinges on execution of AI infrastructure projects, offering substantial upside if targets are met, but high valuation multiples and persistent losses pose risks. Investors must weigh growth potential against financial sustainability and market volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
